Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PKIA antisense RNA 1 (PKIA-AS1) is a long non-coding RNA transcribed from the DNA strand opposite to the PKIA gene locus. Antisense lncRNAs are known to regulate gene expression of their sense counterparts and often participate in the epigenetic, transcriptional, and post-transcriptional modulation of gene activity[1][2]. While the functions of many specific antisense lncRNAs in cancer and cell biology are increasingly documented, there is currently no published evidence linking PKIA-AS1 itself to any specific disease, physiological process, or therapeutic modulation. Antisense lncRNAs in general have been shown to modulate gene expression through recruiting chromatin modifiers, forming RNA duplexes to alter mRNA stability, and influencing transcription factor binding, but individual target information, including for PKIA-AS1, remains sparse[1][2]. PKIA-AS1 is not considered a canonical drug or therapeutic target and has no established role as a clinical biomarker or known interacting drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PKIA antisense RNA 1 (PKIA-AS1).